{"name":"GT Biopharma, Inc.","slug":"gt-biopharma","ticker":"GTBP","exchange":"OTC","domain":"gtbiopharma.com","description":"GT Biopharma, Inc. is a biotech company focused on immuno-oncology. The company is developing a pipeline of therapies targeting various cancer types. With a strong focus on innovation, GT Biopharma aims to revolutionize cancer treatment. Its top drugs include Ladiratuzumab and OXS-355.","hq":"Los Angeles, CA","founded":0,"employees":"","ceo":"Michael Cataldo","sector":"Biotech — Immuno-Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$8M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"Ladiratuzumab patent cliff ($0.00 at risk)","drug":"Ladiratuzumab","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"OXS-355 patent cliff ($0.00 at risk)","drug":"OXS-355","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-14","type":"regulatory","headline":"GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for Ladiratuzumab","summary":"GT Biopharma announced that the FDA has cleared the IND application for Ladiratuzumab, enabling the company to initiate a Phase 1/2 clinical trial.","drugName":"Ladiratuzumab","sentiment":"positive"},{"date":"2023-11-15","type":"earnings","headline":"GT Biopharma Reports Third Quarter 2023 Financial Results","summary":"GT Biopharma reported its third-quarter 2023 financial results, with a net loss of $4.3 million.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitgJBVV95cUxNODFNRFdjX253VGl6Q2RMaURlTVNiVnR6Vi00NElkZURxZ084N1UyTXNzRF9jbzZOcXhqVjViM2pWN2sxX2w4U0xpRlZ4YUhfSVBtQVJIMmMyZEN3MHZWcGM4NGp2QnA3NUI0MWptLXZIWFl4UHVIbVlobHJIaVpGYzJYQkY1U3NiWkoySVYtWjFGU2lEYUZ0WV9FSGNEWktyRzRjbHAtbWlBdXQ5VVgyRGwzd2VOUU8wdnlzTTdZWGR1Z0lkRUw3UEI5LTI4NDZNeDQ5ejJhcFhkRnVUV1lsd3hrM05yRUg2QnVkM0M2VFdINU5yajVXTVN6bGdDQVlJTnNfWDNxNkxFa28tQWhrTTdoQW1sQVh6WGJqbjF4THBuZDZLTy04Nk84ZTlpYjI0UGF1aGxB?oc=5","date":"2026-02-09","type":"regulatory","source":"ABN Newswire","summary":"Ellis Martin Report: GT Biopharma, Inc. (NASDAQ:GTBP) Advances Platform Immuno-Oncology Strategy with FDA-Cleared Solid Tumor IND; An Interview with CEO Michael Breen - ABN Newswire","headline":"Ellis Martin Report: GT Biopharma, Inc. (NASDAQ:GTBP) Advances Platform Immuno-Oncology Strategy with FDA-Cleared Solid ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxQTm9qRFRSdjNtTWdKS0gwMkIwT2R4eGF3OFBnN0tDMHg4MFBYc0tYV0hOYUluUVhieWRLdTktNTNYZjRaQVJ6eEtBV3hYeERtMnV0ZUZZelNDdHZxQk83b08takttQjlDREVFWnVFODJlWTVPU2lCMzFjS1Yxc2FwZTJCZzVVWVFZLXV4NXRJMjNvY2RSMmhvQXdFM0tCVFVEQVRtV1AzT0NlT0pVWktiZkUyV2VaVWFzcE1ZcXlTd1d4QkZEZWFBazgzM1JIVWEwaWlmQ3JqREloZ0puYm5HVUR4SkQ3RTZkTUdSLWJCeWJJd0YzenpUcVZGNGc5c0QtdWhqaDQ2clFrakU?oc=5","date":"2025-12-19","type":"pipeline","source":"Finansavisen","summary":"Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines - Finansavisen","headline":"Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxNRF9UajYwanFhNlJxSV9iUTVVN0RQemtZRHlSY2djWE1HYUYwTTZYb01RNkVaOWQxRDVyenJOTnU2T1Jla3poQ1B0ZkRubXNhUXo3TnZrb2R1MXdOdk9hSTF3NUxCNU0zTUtmUkJOYnZ6ZEV0YlN5b0V0ekRseEZBdXJlczM0VHFKWmVlOXU3WHpiTUprMHdWV1VhRG5ncm52V0xpOTRxWWlmRlZ1R24xUTJHd2hqdV9NMkl3eEc2WVk3MTdFblFOZEpjNGwxN2Q1Vnc?oc=5","date":"2025-12-19","type":"pipeline","source":"PR Newswire","summary":"Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 - PR Newswire","headline":"Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5MTUkzV2wxOExuV1FFS2pnNnUyRkFadFkwWFlqdHBDZXBDUW1MRnJISEVGS1V0VTRraEpaVkNqQU9HbjNSWkhfVzF1OFcyaE15WjRz?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"ZSAN Stock Price, News & Analysis - Stock Titan","headline":"ZSAN Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1CV1FENXNySnpXcElibnJXZFdUMWZJcGdrd0l4T3IzeW1qdC1EMXM4Q0tjalpra2J2YzhnZ1UycUJKTGxBTDNEQlBfcjBFSkJOVEVZ?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"SLRX Stock Price, News & Analysis - Stock Titan","headline":"SLRX Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxORDA3WVRlWmFFM25LNGRKaFFtZEZMYUdESlpKb0lJRHBVZTJqc01mQ0tyUE40N0ZycUpxSmlfWl9jcjhYa24tbmxJXzAzaXJ3UmYtTGpSTW1wUjFfSDZTY21ONU5SN1NHOEhKRUNaVW1tWU1BZmpBWjF4M3FCTjFFVDVYRU1xTGRLMjg4eGxvU2lmNjRXVWNuS2l3RU5naTkzZEY0emFpNlo0WF9pV3dDRWxBanJzdldkYjhiY190MUVkdmVOYWVlb2ZzUzI0a0FTX1NBYWhqRUdLcVNERXhsV0NKQWU?oc=5","date":"2025-01-27","type":"deal","source":"ACCESS Newswire","summary":"GT Biopharma Announces Expanded TriKE(TM) Partnership With Cytovance Biologics - ACCESS Newswire","headline":"GT Biopharma Announces Expanded TriKE(TM) Partnership With Cytovance Biologics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFBmaUVDQzdIeFl0YVppb3ltVDl4Y0RPSGowRUlsUTNxTktXRTFpcERuRmdEeDl0U1BydENlSFVXam96SC1qcVV5UzhYWll6enMw?oc=5","date":"2024-03-26","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE1qQ3pWTlVaY2xQZTBGYUxjYThKTjVYNE13bDJqOXRBaVlfSV9lQzc1aHlNZFFnZi1EY0MyRk4yX2ZNMWlkZk5ucEQzTHczanZTT0x0ZW81ZEdfeEZyZmZxV01Ea21kSjA?oc=5","date":"2023-08-20","type":"pipeline","source":"GuruFocus","summary":"Steven H Ferris Net Worth (2026) - GuruFocus","headline":"Steven H Ferris Net Worth (2026)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE1WLTNOSlBlYkdmbjNBbllranpUTmZYWUJ6UURjbE9ManZPNWljb3JrSWtsQUlxX0NVc1BzMWktT244eEtCZnNaNWl3MldoUFRnSUNjbTZoSVpxNmE5?oc=5","date":"2021-04-09","type":"pipeline","source":"TradingView","summary":"GTBP Stock Price and Chart — NASDAQ:GTBP - TradingView","headline":"GTBP Stock Price and Chart — NASDAQ:GTBP","sentiment":"neutral"}],"patents":[{"drugName":"Ladiratuzumab","drugSlug":"ladiratuzumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0},{"drugName":"OXS-355","drugSlug":"oxs-355","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Roche Holding"],"therapeuticFocus":["Immuno-Oncology"],"financials":null,"yahoo":null}